

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

29 September 2022 (29.09.2022)



(10) International Publication Number

WO 2022/200251 A1

(51) International Patent Classification:

A61K 9/20 (2006.01)

A61P 35/00 (2006.01)

A61K 31/5377 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2022/057305

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(22) International Filing Date:

21 March 2022 (21.03.2022)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/081978

22 March 2021 (22.03.2021) CN

(71) Applicant (for all designated States except ST): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(71) Applicant (for ST only): **ASTRAZENECA INVESTMENT (CHINA) CO. LTD.**, [CN/CN]; No. 7, Lane 898, Halei Lu, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, Shanghai (CN).

(72) Inventors: **SIMPSON, David Bradley Brook**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **REN, Haixia**; AstraZeneca Investment (China) Co. Ltd, No. 7, Lane 898, Halei Lu, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai (CN).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: FORMULATION COMPRISING CERLASERTIB

(57) Abstract: A pharmaceutical formulation which comprises ceralasertib, dibasic calcium phosphate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and magnesium stearate is described.

WO 2022/200251 A1